Circassia closes fundraising to develop allergy therapies

The fund will also be used for completing Phase II testing of its house dust mite and grass allergy T-cell vaccines, based on its proprietary ToleroMune technology.

The UK based Circassia will also use the financing to advance the development programmes for three additional allergy therapies and the recently acquired psoriasis treatment, PAP-1.

Circassia CEO Steve Harris said they have achieved positive Phase II results in their three lead allergy programmes and extended their portfolio into the autoimmunity field.

The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.